Page last updated: 2024-11-08

andrimid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

andrimid: a peptide antibiotic; an anti-Bacillus compound in the marine sponge, Hyatella sp. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID636857
CHEMBL ID425874
SCHEMBL ID3679336
MeSH IDM0233133

Synonyms (5)

Synonym
108868-95-7
andrimid
CHEMBL425874
(2e,4e,6e)-n-[(1s)-3-[[(2s)-3-methyl-1-[(3r,4s)-4-methyl-2,5-dioxopyrrolidin-3-yl]-1-oxobutan-2-yl]amino]-3-oxo-1-phenylpropyl]octa-2,4,6-trienamide
SCHEMBL3679336

Research Excerpts

Overview

Andrimid is reported to be a novel kind of polyketide-nonribosomal peptide hybrid product (PK-NRPs) that inhibits fatty acid biosynthesis in bacteria. Andrimid blocks the carboxyl-transfer reaction of bacterial acetyl-CoACarboxylase.

ExcerptReferenceRelevance
"Andrimid is reported to be a novel kind of polyketide-nonribosomal peptide hybrid product (PK-NRPs) that inhibits fatty acid biosynthesis in bacteria. "( Improved production of andrimid in Erwinia persicina BST187 strain by fermentation optimization.
Cheng, T; Ge, T; Hou, Y; Xia, J; Zhao, L, 2023
)
2.66
"Andrimid is a hybrid nonribosomal peptide-polyketide antibiotic that blocks the carboxyl-transfer reaction of bacterial acetyl-CoA carboxylase (ACC) and thereby inhibits fatty acid biosynthesis with submicromolar potency. "( Andrimid producers encode an acetyl-CoA carboxyltransferase subunit resistant to the action of the antibiotic.
Fortin, PD; Liu, X; Walsh, CT, 2008
)
3.23
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID247897Inhibitory concentration of the compound against Staphylococcus aureus was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
AID245202Minimum inhibitory concentration against Streptococcus pneumoniae G9A strain was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
AID245102Minimum inhibitory concentration of the compound against Staphylococcus aureus 133 strain was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
AID245089Minimum inhibitory concentration of the compound againstEscherichia coli Neumann strainwas determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
AID245074Minimum inhibitory concentration of the compound againstEscherichia coli HN818 strain was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
AID247792Inhibitory concentration of the compound against Escherichia coli was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (10.53)18.2507
2000's8 (42.11)29.6817
2010's7 (36.84)24.3611
2020's2 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.58 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]